Abstract
Background Spatial transcriptomics (ST) data provide spatially-informed gene expression for studying complex diseases such as Alzheimer’s disease (AD). Existing studies using ST data to identify genes with spatially-informed differential gene expression (DGE) of complex diseases have limited power due to small sample sizes. Conversely, single-nucleus RNA sequencing (snRNA-seq) data offer larger sample sizes for studying cell-type specific (CTS) DGE but lack spatial information. In this study, we integrated ST and snRNA-seq data to enhance the power of spatially-informed CTS DGE analysis of AD-related phenotypes.
Method First, we utilized the recently developed deep learning tool CelEry to infer the spatial location of ∼1.5M cells from snRNA-seq data profiled from dorsolateral prefrontal cortex (DLPFC) tissue of 436 postmortem brains in the ROS/MAP cohorts. Spatial locations of six cortical layers that have distinct anatomical structures and biological functions were inferred. Second, we conducted cortical-layer specific (CLS) and CTS DGE analyses for three quantitative AD-related phenotypes –– β-amyloid, tangle density, and cognitive decline. CLS-CTS DGE analyses were conducted based on linear mixed regression models with pseudo-bulk scRNA-seq data and inferred cortical layer locations.
Results We identified 450 potential CLS-CTS significant genes with nominal p-values<10-4, including 258 for β-amyloid, 122 for tangle density, and 127 for cognitive decline. Majority of these identified genes, including the ones having known associations with AD (e.g., APOE, KCNIP3, and CTSD), cannot be detected by traditional CTS DGE analyses without considering spatial information. We also identified 8 genes shared across all three phenotypes, 21 between β-amyloid and tangle density, 10 between cognitive decline and tangle density, and 10 between β-amyloid and cognitive density. Particularly, Gene Set Enrichment Analyses with the CLS-CTS DGE results of microglia in cortical layer-6 of β-amyloid identified 12 significant AD-related pathways.
Conclusion Incorporating spatial information with snRNA-seq data detected significant genes and pathways for AD-related phenotypes that would not be identified by traditional CTS DGE analyses. These identified CLS-CTS significant genes not only help illustrate the pathogenesis of AD, but also provide potential CLS-CTS targets for developing therapeutics of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS, R35GM138313, for J.Y). ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All ROSMAP participants enrolled without known dementia and agreed to detailed clinical evaluation and brain donation at death [https://pubmed.ncbi.nlm.nih.gov/29865057/]. Both studies were approved by an Institutional Review Board of Rush University Medical Center (ROS IRB# L91020181, MAP IRB# L86121802). Both studies were conducted according to the principles expressed in the Declaration of Helsinki. Each participant signed an informed consent, Anatomic Gift Act, and an RADC Repository consent (IRB# L99032481) allowing her data and biospecimens to be repurposed. ROS/MAP transcriptomics data were shared with a data use agreement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
List of abbreviations
- ST
- Spatial transcriptomics
- AD
- Alzheimer’s disease
- DGE
- differential gene expression
- snRNA-seq
- single-nucleus RNA sequencing
- DLPFC
- dorsolateral prefrontal cortex
- CLS
- cortical-layer specific
- CTS
- cell-type specific
- LIBD
- Lieber Institute for Brain Development
- ROS/MAP
- the Religious Order Study (ROS) and the Rush Memory and Aging Project
- Ast
- astrocytes
- Ex
- excitatory neurons
- In
- inhibitory neurons
- Mic
- microglia
- Oli
- oligodendrocytes
- Opc
- oligodendrocyte precursor cells
- AD-NC
- Alzheimer’s disease neuropathologic changes
- LMM
- Linear mixed model Kullback–Leibler divergence
- KL
- divergence
- GSEA
- Gene Set Enrichment Analysis
